Anthony R. Mato, MD, MSCE, is an associate member at Memorial Sloan Kettering Cancer Center (MSKCC) and director of the Chronic Lymphocytic Leukemia (CLL) Program at MSKCC in New York. His research on the development of clinical and translational trials for patients with CLL focuses on novel immunotherapies and immune checkpoint inhibitors. Dr Mato’s outcomes-related research explores health indicators among CLL patients in real-world settings. A well-published scholar, he regularly contributes articles to peer-reviewed journals, including Blood and Lancet Oncology. Dr Mato is a member of various societies, including the American Society of Clinical Oncology, and is on the medical advisory board of the CLL Society, a patient-centric, physician-curated nonprofit organization.

Matthew S. Davids, MD, MMSC, is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies and associate director of the CLL Center at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston. He has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate a variety of novel therapeutic strategies in patients with CLL and other hematologic malignancies. Dr Davids received his medical degree from Yale School of Medicine in New Haven, Connecticut.